The White Cell Foundation (TWCF) is a non-profit organization established to create awareness about blood cancers in Nigeria and to provide support for people with blood cancers and their families.
To improve the survival and quality of life of people with blood cancers and their families in Nigeria.
The 3-prong approach to accomplish our mission:
- Research: Conduct research to find innovative solutions to the challenges of blood cancer in Nigeria.
- Support: Provide support for blood cancer patients and their families.
- Awareness: Create awareness about blood cancers.
The Cancer Support Community (CSC) is a global non-profit network of 175 locations, including CSC and Gilda’s Club centers, hospital and clinic partnerships, and satellite locations that deliver more than $50 million in free support services to patients and families.
The in-person locations alone record 500,000 visits each year. In addition, CSC administers a toll-free helpline
and produces award-winning educational resources that, together with the locations, reach more than one million people each year. Formed in 2009 by the merger of The Wellness Community and Gilda’s Club, CSC also conducts cutting-edge research on the emotional, psychological, and financial journey of cancer patients.
In addition, CSC advocates at all levels of government for policies to help individuals whose lives have been disrupted by cancer. In January 2018, CSC welcomed Denver-based nonprofit MyLifeLine.org, a digital community that
includes 35,000 patients, caregivers, and their supporters that will enable CSC to scale its digital services in an innovative, groundbreaking way.
The Foundation was founded in 2002 and is governed by an Executive body of twelve persons. Our Mission is to provide Comprehensive support for persons affected with blood related cancers in Barbados.
- SUPPORT: To provide a support network for suffers for blood related cancers and their families.
- EDUCATION: To educate patients, their families, caregivers and the Barbadian public about blood cancers.
- ADVOCACY: To act as an agent on behalf of such persons on matters pertaining to blood related cancers.
- FINANCIAL: To assist financially where possible.
- Upon diagnosis of the specific type of haematological cancer the patient has, educational material is given to the patients and family member.
- Bi-weekly Educational and counselling Session at the Haematology Clinic of Elizabeth Hospital. 3. MLLF offers educational outreach in the community as the need arises and upon request from organization and Service – Clubs, Schools also from persons in the community.
- MLLF has established the Dalton Durant patient Assistance and Prescription Medication Programme for patients who are unable to purchase their medication, when these medications are not on the Barbados Drug Formulary.
- Assistance is given for other medical services. X-rays, MRI, Blood Tests and other Laboratory tests. At times, a small donation is given to a patient going overseas for treatments. We also provide for non-medical items such as food items, the house rent, school supply and any other assistance that may occurred.
- Funeral Grant: This grant was established to assist very needy families in their most difficult times.
SOCIAL WELFARE SERVICES:
- The MLLF provides for home and hospital visits.
- We supply toiletries, food items, floral arrangements, wheelchairs and any other services that are appropriate to patients during hospitalization and home visits.
- Furniture and equipment are donated to the Queen Elizabeth Hospital, Haematological Clinic for patient’s use.
- The Dalton Durant HAEMATOLOGICAL CANCER REGISTRY 2005-2009.
- We were able to ascertain from the data collected in this registry the most frequent blood cancers in Barbados.
- The MLLF is committed to research and will assist financially in this area.
FUNDING: The Foundation receives its funding through Fund-raising, Corporate and other donation made to the foundation.
Since 1977, our work has been made possible through our fundraising events and the generous support we receive from individuals, companies, trusts and grants. We do not receive government funding.
Funding goes to our core services: Patient Support, Research, Information, Awareness & Advocacy
We aim to provide support where and when it is needed most. Our free and personalised services range from just having someone to talk to in our Support Services team, to disease-specific information and resources.
The suddenness with which these diseases strike can often put enormous financial strain on people. To those experiencing difficulties we may be able to offer support including food or petrol vouchers, or help with paying utility bills. Each case is assessed on an individual basis.
LBC is committed to finding better treatments and cures. We are the only dedicated funder of haematology research in New Zealand. Annually, we provide travel grants to health professionals, including scientists, clinicians, nurses and laboratory staff to attend local and international meetings, keep up to date with the latest advancements and conduct vital research.
The Leukaemia Foundation is the only Australian charity helping those with leukaemia, lymphoma, myeloma, MDS and related blood disorders survive and live a better quality of life.
Each day, another 35 Australians are diagnosed. Although improved treatments and care are helping more people survive, sadly someone loses their life to blood cancer every two hours. Blood cancer is the third most common cause of cancer death in Australia, claiming more lives than breast cancer or melanoma.
Helping local families beat blood cancer
Each year, the Leukaemia Foundation helps hundreds of families from regional and rural Australia by providing free accommodation in our capital cities so they can access life-saving treatment at major hospitals. Our transport service also helps thousands get to and from medical appointments, driving more than one million kilometres each year to ensure people get the medicines they need to beat their blood cancer. Thanks to its supporters, the Leukaemia Foundation is also able to provide counselling, comprehensive information, education and support programs and financial assistance to help the 60,000 Australians who are currently living with a blood cancer.
Helping Australian researchers beat blood cancer
Researchers funded by generous supporters of the Leukaemia Foundation are working tirelessly to discover safer and more effective treatments that will save lives and help people lead a better quality
of life. Our $38m cancer research program has been running for more than a decade and finds the causes of blood cancer and improves the way people are diagnosed and then treated. The Leukaemia Foundation gives those impacted by blood cancer a strong voice, advocating for change and ensuring all Australians who need them have easy access to the very best blood cancer treatments.
L’association Connaître et Combattre les Myélodysplasies regroupe, depuis juillet 2006, des personnes atteintes de syndrome myélodysplasique et leurs proches.
L’association a l’appui du Groupe Francophone des Myélodysplasies (GFM).
- Favoriser les échanges d’information entre les patients et leurs proches à une échelle nationale et régionale.
- Favoriser la recherche sur les myélodysplasies et la mise en place de nouveaux médicaments et traitements, en liaison avec les médecins du GFM.
- Contribuer au progrès des soins et de la prise en charge des patients.
- Faciliter la relation des adhérents avec les spécialistes des myélodysplasies. Soutenir l’action du Groupe Francophone des Myélodysplasies (GFM) et collaborer avec lui.
- Maintenir une veille sur les progrès obtenus dans le monde et organiser des réunions d’information en présence de spécialistes.
Since July 2006, our association has been supporting people suffering from Myelodysplastic Syndrome and their relatives with the help of the Francophone Group of Myelodysplasia (GFM).
Our objectives are:
- Encourage the exchange of information between patients and their families at a national and regional level.
- Promote research on MDS and the introduction of new drugs and treatments, in collaboration with GFM doctors.
- Contributing to the advancement of patient treatment and care.
- Facilitate the relationship of its members with MDS specialists. Support and collaborate with the Francophone Group of Myelodysplasia (GFM).
- Keep up-to-date with the latest progress achieved around the world and organize informational meetings for patients with the presence of MDS specialists.
The MDS Foundation, Inc. is an international organization established in 1994 by world renowned researchers dedicated to further scientific knowledge, patient support, and education in the myelodysplastic syndromes (MDS).
The Foundation is based on the premise that international cooperation will accelerate the process leading to the control and cure of MDS. The Foundation provides research grants for scientific investigators, sponsors international working groups of scientists and physicians to further diagnostic, prognostic and treatment techniques, and disseminates information on state of the art research, clinical trials and treatments among the profesional and patient communities.
The Foundation also refers patients to its collection of ‘MDS Centers of Excellence,’ maintains an electronic fórum on its website for interaction and Support among patients, and provides educational programs for both health care professionals and patients and their families.
The Aplastic Anemia & MDS International Foundation is the world’s leading non-profit health organization dedicated to supporting patients and their families who are living with aplastic anemia, myelodysplastic syndromes (MDS) and paroxysmal nocturnal hemoglobinuria (PNH) and related bone marrow failure diseases.
We are a patient-focused, patient-centered organization serving patients and families throughout the three phases of bone marrow failure diseases:
- The life-changing phase of diagnosis
- The life threatening phase of treatment
- The lifelong phase of living with a chronic disease
The Aplastic Anemia & MDS International Foundation provides answers, support and hope to thousands of patients and their families around the world.
The Aplastic Anemia & Myelodysplasia Association of Canada (AAMAC) is a volunteer-run organization supporting patients and caregivers across the country who are living with aplastic anemia, myelodysplastic syndrome (also called MDS or myelodysplasia) and paroxysmal nocturnal hemoglobinuria (PNH).
In addition to supporting patients and caregivers AAMAC also:
- provides funds for research
- works to increase awareness
- provides education
- support for blood, bone marrow and stem cell donations
We are the only group dedicated solely to MDS in the UK.
“Support, Information, Awareness and Campaigns for those affected by Myelodysplastic Syndromes”.
The majority of our committee members are either MDS patients themselves or relatives of a patient.
We were formally set up in 2008 and have two full-time employees as well as a part-time volunteer.
We are funded by donations, fundraisers and pharmaceutical grants.
We are delighted to cooperate with other MDS groups anywhere in the world – and look forward to meeting any new members to share best practices.
Our aims are:
- To provide a networking service through which those newly diagnosed with MDS can share their experience with fellow sufferers.
- To provide a help and advice telephone line 5 days a week.
- To organise several national patient information meetings with specialist speakers.
- To help patients create small regional support group meetings, to meet informally – or organise activities or small presentations.
- To distribute information and raise awareness of MDS among patients, carers and health care professionals across the UK.
- To provide access to a list of UK consultants, specialising in MDS.
- To develop and maintain a website, providing information on MDS, latest news or research and clinical trials and a very active Patients Forum.
- To run two Facebook pages (one public, one per invitation only) and a Twitter account.
- To fund a research activity in MDS, that will benefit patients